1. Home
  2. SLRC vs AKBA Comparison

SLRC vs AKBA Comparison

Compare SLRC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLRC
  • AKBA
  • Stock Information
  • Founded
  • SLRC 2007
  • AKBA 2007
  • Country
  • SLRC United States
  • AKBA United States
  • Employees
  • SLRC N/A
  • AKBA N/A
  • Industry
  • SLRC Finance/Investors Services
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLRC Finance
  • AKBA Health Care
  • Exchange
  • SLRC Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • SLRC 889.2M
  • AKBA 958.6M
  • IPO Year
  • SLRC 2010
  • AKBA 2014
  • Fundamental
  • Price
  • SLRC $15.89
  • AKBA $3.72
  • Analyst Decision
  • SLRC Hold
  • AKBA Strong Buy
  • Analyst Count
  • SLRC 6
  • AKBA 5
  • Target Price
  • SLRC $15.79
  • AKBA $6.90
  • AVG Volume (30 Days)
  • SLRC 161.2K
  • AKBA 3.2M
  • Earning Date
  • SLRC 08-05-2025
  • AKBA 08-07-2025
  • Dividend Yield
  • SLRC 10.32%
  • AKBA N/A
  • EPS Growth
  • SLRC N/A
  • AKBA N/A
  • EPS
  • SLRC 1.61
  • AKBA N/A
  • Revenue
  • SLRC $227,510,000.00
  • AKBA $184,909,000.00
  • Revenue This Year
  • SLRC N/A
  • AKBA $27.95
  • Revenue Next Year
  • SLRC $0.22
  • AKBA $43.88
  • P/E Ratio
  • SLRC $9.87
  • AKBA N/A
  • Revenue Growth
  • SLRC N/A
  • AKBA N/A
  • 52 Week Low
  • SLRC $13.64
  • AKBA $1.07
  • 52 Week High
  • SLRC $17.94
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • SLRC 35.79
  • AKBA 51.26
  • Support Level
  • SLRC $15.93
  • AKBA $3.47
  • Resistance Level
  • SLRC $16.60
  • AKBA $3.81
  • Average True Range (ATR)
  • SLRC 0.22
  • AKBA 0.17
  • MACD
  • SLRC -0.06
  • AKBA -0.04
  • Stochastic Oscillator
  • SLRC 17.77
  • AKBA 43.86

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: